|
RCUS | Arcus Biosciences, Inc. |
|
|
RCUS | Arcus Biosciences, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.79 |
| Leverage | 45.47% |
| Market Cap | $ 2.3B |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -367.8m |
| Margin | -139.04% |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.